Key result
Rivaroxaban use in Japanese patients with non-valvular atrial fibrillation resulted in a low incidence rate of symptomatic stroke and systemic embolism (1.0%/year).
Why the study?
Does rivaroxaban prevent stroke and systemic embolism in Japanese patients with non-valvular atrial fibrillation?
Population
7,141 Japanese patients ≥20 years of age with non-valvular atrial fibrillation, mean age 71.6 years, mean…
Design
Cohort
Follow-up
average 897.1 days
Authors
Loading...
May inform anticoagulation in Japanese non-valvular AF; extends real-world data but leaves randomized confirmation open.
Cohort (n=7,141)
Yes
Does rivaroxaban prevent stroke and systemic embolism in Japanese patients with non-valvular atrial fibrillation?
In a real-world Japanese cohort, rivaroxaban demonstrated low rates of stroke, systemic embolism, and major bleeding in patients with non-valvular atrial fibrillation.
Shimokawa et al. (2018) conducted a cohort in non-valvular atrial fibrillation (NVAF) (n=7,141). Rivaroxaban was evaluated on symptomatic stroke and systemic embolism (SE). Rivaroxaban use in Japanese patients with non-valvular atrial fibrillation resulted in a low incidence rate of symptomatic stroke and systemic embolism (1.0%/year).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: